1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,480 | 2,700 | 10:20 | |
| 2,500 | 2,680 | 10:17 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.10. | Addex Therapeutics: ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES | 309 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, October 29, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 08.10. | Addex Therapeutics: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia | 537 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR
Geneva, Switzerland, October 8, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 02.10. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 02.10. | Addex Therapeutics Announces Executive Management Changes | 491 | GlobeNewswire (Europe) | Jean-Philippe Rocher Appointed Head of Pharmaceutical DevelopmentMikhail Kalinichev, Head of Translational Science, Steps Down
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland... ► Artikel lesen | |
| 30.09. | Addex Therapeutics Raises $2.8 Million As GABAB Programs Advance | 4 | pulse2.com | ||
| ADDEX THERAPEUTICS SA ADR Aktie jetzt für 0€ handeln | |||||
| 28.09. | Addex Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript | 2 | Benzinga.com | ||
| 28.09. | Addex Therapeutics H1 Net Loss Widens, Operating Loss Narrows; Advances GABAB PAM Cough Program | 2 | RTTNews | ||
| 28.09. | Addex Therapeutics reports 1H results | 6 | Seeking Alpha | ||
| 28.09. | Addex bringt Programme im zweiten Quartal weiter voran | 446 | Moneycab | Genf - Das Biotechunternehmen Addex ist im zweiten Quartal erwartungsgemäss in den roten Zahlen geblieben. Die liquiden Mittel beliefen sich per Ende Juni 2026 auf 0,8 Millionen Franken. Einnahmen verbuchte... ► Artikel lesen | |
| 28.09. | Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update | 472 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, September 28, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 25.09. | Indivior ends PAM drug collab with Addex ahead of Supernus merger | 1 | FierceBiotech | ||
| 25.09. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.09. | Addex Therapeutics: Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior | 536 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR
Geneva, Switzerland, September 25, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing... ► Artikel lesen | |
| 24.09. | Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026 | 519 | GlobeNewswire (Europe) | Geneva, Switzerland, September 24, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric... ► Artikel lesen | |
| 28.08. | Addex beschafft sich im Rahmen seines ATM-Vertrags 2,8 Millionen US-Dollar | 637 | Moneycab | Genf - Addex Therapeutics (SIX und Nasdaq: ADXN), ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich auf die Entwicklung eines Portfolios neuartiger kleinmolekularer allosterischer... ► Artikel lesen | |
| 26.08. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 26.08. | Addex Therapeutics raises $2.8M via ATM offering, extending runway to Q4 2027 | 1 | Seeking Alpha | ||
| 26.08. | Addex Therapeutics: ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027 | 589 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, August 26, 2026
-
Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 08.07. | Addex Therapeutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 08.07. | Addex Therapeutics: Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness | 593 | GlobeNewswire (Europe) | Ad Hoc Announcement Pursuant to Art.?53 LR
Geneva, Switzerland, July 8, 2026
-
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing... ► Artikel lesen |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 0,380 | +4,97 % | EyePoint auf der Stifel Healthcare Conference 2026: Strategischer Schwenk auf DME nach Rückschlag bei feuchter AMD | ||
| ASSEMBLY BIOSCIENCES | 18,760 | -1,78 % | Assembly Biosciences: Phase 2 läuft - was jetzt zählt | ||
| AMARIN | 10,300 | +0,98 % | Amarin presents cardiovascular research data at AHA meeting | ||
| FILANA THERAPEUTICS | 0,456 | +4,71 % | FILANA THERAPEUTICS, INC. - 10-Q, Quarterly Report | ||
| COMPASS PATHWAYS | 8,550 | +3,01 % | Compass Pathfinder Limited: Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression | Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000... ► Artikel lesen | |
| ALTIMMUNE | 1,724 | -0,58 % | Altimmune, Inc: Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting 2026 in Patients with Alcohol Use Disorder | ||
| ACHIEVE LIFE SCIENCES | 5,650 | -1,74 % | ACHIEVE LIFE SCIENCES, INC. - 10-Q, Quarterly Report | ||
| CORBUS PHARMACEUTICALS | 3,506 | -0,06 % | Corbus Pharmaceuticals Holdings, Inc. - 10-Q, Quarterly Report | ||
| AURINIA PHARMACEUTICALS | 14,245 | -2,40 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 4,220 | -1,40 % | IRONWOOD PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| GALECTIN THERAPEUTICS | 2,680 | -11,84 % | Galectin Therapeutics to present NASH cirrhosis trial data at AASLD | ||
| DARE BIOSCIENCE | 0,692 | 0,00 % | Daré Bioscience, Inc.: Daré Bioscience Releases Next Episode in "CEO Corner" Video Series | ||
| GRACE THERAPEUTICS | 1,860 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,498 | +1,06 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,710 | +0,59 % | Biodexa reports progress on FAP and GIST drug trials |
Das Unternehmen ADDEX THERAPEUTICS SA ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADDEX THERAPEUTICS SA ADR finden Sie auf Wallstreet Online.